.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Accenture
Harvard Business School
Chubb
Dow
Colorcon
Fish and Richardson
Deloitte
Express Scripts
Healthtrust

Generated: September 19, 2017

DrugPatentWatch Database Preview

Dr Reddys La Company Profile

« Back to Dashboard

What is the competitive landscape for DR REDDYS LA, and when can generic versions of DR REDDYS LA drugs launch?

DR REDDYS LA has one hundred and seventy-six approved drugs.

There are five US patents protecting DR REDDYS LA drugs on DR REDDYS LA drugs in the past three years. There are eleven tentative approvals on DR REDDYS LA drugs.

There are ninety-four patent family members on DR REDDYS LA drugs in forty-eight countries.

Summary for Applicant: Dr Reddys La

Patents:5
Tradenames:138
Ingredients:122
NDAs:176
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Ltd
GEMCITABINE HYDROCHLORIDE
gemcitabine hydrochloride
INJECTABLE;INJECTION202997-001May 7, 2013APRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
OMEPRAZOLE
omeprazole
CAPSULE, DELAYED REL PELLETS;ORAL075576-002Oct 22, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
ZONISAMIDE
zonisamide
CAPSULE;ORAL077645-001Dec 22, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
LEVETIRACETAM
levetiracetam
TABLET;ORAL076920-003Jan 15, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
AUGMENTIN '400'
amoxicillin; clavulanate potassium
FOR SUSPENSION;ORAL050725-002May 31, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
OMEPRAZOLE
omeprazole
CAPSULE, DELAYED REL PELLETS;ORAL075576-003Oct 22, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM
amlodipine besylate; atorvastatin calcium
TABLET;ORAL203874-002Mar 7, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
OLANZAPINE
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL076534-001Oct 24, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
fexofenadine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL079043-002Jun 22, 2011OTCNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
IRBESARTAN AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; irbesartan
TABLET;ORAL203500-001Sep 27, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Dr Reddys La

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-004Nov 12, 1999► Subscribe► Subscribe
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-005Nov 12, 1999► Subscribe► Subscribe
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-005Nov 12, 1999► Subscribe► Subscribe
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-004Nov 12, 1999► Subscribe► Subscribe
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-006Nov 12, 1999► Subscribe► Subscribe
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-006Nov 12, 1999► Subscribe► Subscribe
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-004Nov 12, 1999► Subscribe► Subscribe
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-006Nov 12, 1999► Subscribe► Subscribe
Dr Reddys Labs Sa
HABITROL
nicotine
FILM, EXTENDED RELEASE;TRANSDERMAL020076-005Nov 12, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DR REDDYS LA drugs

Drugname Dosage Strength Tradename Submissiondate
omeprazole
Delayed-release Tablets20 mg
OMEPRAZOLE
6/3/2015
amoxicillin and clavulanate potassium
Extended-release Tablets1000 mg/62.5 mg
AUGMENTIN XR
1/21/2009

Non-Orange Book Patents for Dr Reddys La

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,294,199 Method of treating a bacterial infection comprising administering amoxycillin► Subscribe
6,660,299 Modified release pharmaceutical formulation comprising amoxycillin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Dr Reddys La Drugs

Country Document Number Estimated Expiration
Eurasian Patent Organization004310► Subscribe
Uruguay26104► Subscribe
Belgium1013309► Subscribe
European Patent Office1044680► Subscribe
Slovenia1044680► Subscribe
African Regional IP Organization (ARIPO)200102284► Subscribe
China1225246► Subscribe
African Intellectual Property Organization (OAPI)11926► Subscribe
Portugal1044680► Subscribe
Germany20006626► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Dr Reddys La Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1730131/02Switzerland► SubscribePRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
C/GB97/023United Kingdom► SubscribePRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
C0036France► SubscribePRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
C/GB98/047United Kingdom► SubscribePRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
0625Netherlands► SubscribePRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
496Luxembourg► SubscribePRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
C/GB05/010United Kingdom► SubscribePRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
/1998Austria► SubscribePRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
C/GB01/006United Kingdom► SubscribePRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
US Army
Merck
Farmers Insurance
Cantor Fitzgerald
Novartis
Fish and Richardson
Moodys
Teva
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot